Abstract
This chapter presents several model-based phase I/II designs, including the EffTox design (Thall & Cook, 2004), the logistic model-based design (Zang et al., 2014), a Bayesian phase I/II design for immunotherapy (Liu et al., 2018), and an isotonic design (Zang et al., 2014). These designs assume a dose-toxicity and dose-efficacy model, and continuously update the estimate of the model in a way similar to the continual reassessment method (CRM). The model estimate is then used to guide dose escalation/de-escalation. Herein, the software of these designs is introduced.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bachmayr-Heyda, A., Aust, S., Heinze, G., Polterauer, S., Grimm, C., Braicu, E. I., Sehouli, J., Lambrechts, S., Vergote, I., Mahner, S., Pils, D., Schuster, E., Thalhammer, T., Horvat, R., Denkert, C., Zeillinger, R., & Castillo-Tong, D. (2013). Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients-a study of the OVCAD consortium. BMC Cancer, 13, 422. https://doi.org/10.1186/1471-2407-13-422
Brock, K. (2019). trialr: Bayesian clinical trial designs in R and Stan. arXiv preprint arXiv:1907.00161
Brock, K., Billingham, L., Copland, M., Siddique, S., Sirovica, M., & Yap, C. (2017). Implementing the EffTox dose-finding design in the Matchpoint trial. BMC Medical Research Methodology, 17(1), 1–15.
Brunk, H. D., Barlow, R. E., Bartholomew, D. J., & Bremner, J. M. (1972). Statistical inference under order restrictions.(the theory and application of isotonic regression). Missouri University of Columbia Department of Statistics.
Liu, S., Guo, B., & Yuan, Y. (2018). A Bayesian phase I/II trial design for immunotherapy. Journal of the American Statistical Association, 113(523), 1016–1027.
Mu, R., Xu, G., Liu, G., & Pan, H. (2021). A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials. Contemporary Clinical Trials, 108, 106504.
Pardoll, D. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Review Cancer, 12, 252–264.
Rogatko, A., Schoeneck, D., Jonas, W., Tighiouart, M., Khuri, F. R., & Porter, A. (2007). Translation of innovative designs into phase I trials. Journal of Clinical Oncology, 25(31), 4982–4986.
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., & Ambrosone, C. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/Regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 102, 18538–18543.
Thall, P. F., & Cook, J. D. (2004). Dose-finding based on efficacy-toxicity trade-offs. Biometrics, 60(3), 684–693.
Zang, Y., Lee, J. J., & Yuan, Y. (2014). Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials, 11(3), 319–327.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pan, H., Yuan, Y. (2023). Model-Based Designs for Identification of Optimal Biological Dose. In: Bayesian Adaptive Design for Immunotherapy and Targeted Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-19-8176-0_4
Download citation
DOI: https://doi.org/10.1007/978-981-19-8176-0_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-8174-6
Online ISBN: 978-981-19-8176-0
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)